Biomea Fusion Q1 net loss $12.4M; cash $45.1M; icovamenib Phase II T2D data due Q4 2026

Biomea Fusion, Inc.

2026-Q1 EPS reported -$0.17 vs consensus -$0.24 ▲ beat (+29.8%)

Net loss $12.4M ($1.6M SBC) vs $29.3M in Q1 2025; cash, equivalents & restricted cash $45.1M at Mar 31, 2026; runway into Q1 2027.
R&D expenses $9.1M (down from $22.9M YoY); G&A $3.7M (down from $6.8M).
Icovamenib chronic tox studies completed; Phase II T2D trials COVALENT-211/-212 dosing; topline 26-week data expected Q4 2026.
Phase II T1D COVALENT-112: 52% C-peptide AUC increase at week 12 (200mg); preservation through week 52; plan for investigator-sponsored trial.
Phase I GLP-1 obesity trial (BMF-650, GLP-131) ongoing; initial 28-day weight data expected Q2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biomea Fusion, Inc. reported first quarter ended March 31, 2026 results: net income net loss of $12.4 million.

Period: first quarter ended March 31, 2026
Net income: net loss of $12.4 million
Result: reported results

Exact text from the filing

Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Biomea Fusion, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-217037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.